Brought to you by 
Daewoong takes 30.2% stake in fellow Korean pharmaco HanAll
05 May 2022
Executive Summary
Daewoong Pharmaceutical Co. Ltd. acquired a 30.2% stake in HanAll Pharmaceutical Co. Ltd. Daewoong paid $94.1mm (KRW104.6bn) for 15.5mm HanAll shares (consisting of 6mm existing shares owned by HanAll chairman Kim Byung-tae and 9.5mm new shares through a rights offering), implying a $6.07 per-share price (an 8% discount).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Drug Delivery
- Generic Drugs
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Daewoong takes 30.2% stake in fellow Korean pharmaco HanAll
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice